Company profile: Certis Oncology
1.1 - Company Overview
Company description
- Provider of precision oncology and translational science solutions, including Certis Oncology Intelligence® for predictive therapeutic response data from advanced cancer models with AI-driven bioinformatics; BarneyOI® cancer model database; CertisAI™ drug response prediction; O-PDX models; 3D cell cultures; and custom in vitro pharmacology and ex vivo assays, including cell line development, to help bridge the preclinical–clinical translation gap.
Products and services
- Certis Oncology Intelligence®: AI-enhanced platform that delivers highly predictive therapeutic response data derived from advanced models of cancer, helping therapeutics developers bridge the translation gap between preclinical studies and clinical trials
- CertisAI™: Biomarker-guided, AI-driven platform that predicts individual drug responses using gene expression biomarkers and multivariate analyses for precision oncology and translational research
- BarneyOI® Cancer Model Database: Queryable database offering access to highly characterized cancer models for preclinical studies, with features for detailed queries and model selection to streamline study planning
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Certis Oncology
Hammersmith Medicines Research
HQ: United Kingdom
Website
- Description: Provider of contract research services for phase 1 and early phase 2 clinical trials, including volunteer recruitment, trial design, data management and statistical analysis. Offers laboratory services (biomarker assays, DNA extraction/PCR, flow cytometry, ELISA), pharmacy manufacturing (sterile/non-sterile, radiopharmaceuticals), QA and regulatory compliance (GMP, ISO 27001), and accredited COVID-19 testing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Hammersmith Medicines Research company profile →
Boca Biolistics
HQ: United States
Website
- Description: Provider of hybrid CRO and biobank services, delivering human biospecimens across oncology and other diseases; end-to-end contract research to support development and market approval of diagnostic technologies; CLIA-certified, CAP-accredited reference lab testing; COVID-19 serology and PCR; and oncology research solutions combining clinical research, data analytics, and industry leading clinical and molecular datasets to enable precision medicine.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Boca Biolistics company profile →
Qointa
HQ: Belgium
Website
- Description: Provider of a compliant, validated eHealth platform for device-agnostic patient monitoring and coaching, enabling direct randomization into adaptive clinical trials. Offers digital transformation and software validation solutions, quality and regulatory support (QMS and risk management), medical device software development, and electronic data integrity services.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qointa company profile →
Reverba
HQ: United States
Website
- Description: Provider of patient engagement solutions for pharmaceutical and biotechnology companies, including clinical patient engagement programs powered by the reverbaBRIDGE platform, global clinical trial optimization with patient-centered approaches and real-time data insights, expert recruitment, tech-enabled relationship management and automation, and total compliance with HIPAA, GDPR, and FDA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reverba company profile →
ShangPharma Innovation
HQ: United States
Website
- Description: Provider of global innovation incubation and investment focused on biomedical R&D technologies and therapeutics.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ShangPharma Innovation company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Certis Oncology
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Certis Oncology
2.2 - Growth funds investing in similar companies to Certis Oncology
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Certis Oncology
4.2 - Public trading comparable groups for Certis Oncology
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →